We selected a heterogeneous panel of commercially available cell lines including one non-tumor cell line, HPDE (human pancreatic ductal epithelial); three epithelial-phenotype cell lines BxPC-3, SUIT-2.028, and CAPAN-1 (with BxPC-3 being KRAS wild-type); and one mesenchymal-phenotype cell SUIT-2.007. The gene discussed is KRAS; the disease is neoplasm.